Percutaneous coronary intervention in patients with active bleeding or high bleeding risk

Area of Science:

• Cardiology
• Interventional Cardiology

Background:

• Limited randomized clinical trial (RCT) evidence exists for percutaneous coronary intervention (PCI) in patients with high bleeding risk or active bleeding.
• Current management decisions often rely on subgroup analyses from RCTs or expert opinions.

Observation:

• Peri-PCI bleeding is associated with increased mortality.
• PCI may be considered if bleeding can be mechanically controlled and patients tolerate anticoagulation for 4 hours.
• Unfractionated heparin or bivalirudin are suggested for patients with high bleeding risk.
• For patients on chronic oral anticoagulants, PCI may proceed without additional antithrombotic therapy if INR is 2-3.

Findings:

• Antiplatelet therapy may be necessary if new thrombi form in the treated artery.
• The decision to proceed with PCI versus conservative management requires a case-by-case evaluation.
• PCI can be performed if the anticipated benefits outweigh the bleeding risks.

Implications:

• Highlights the need for evidence-based guidelines for PCI in high-risk bleeding populations.
• Emphasizes individualized patient management balancing thrombotic and bleeding risks.
• Suggests potential anticoagulation and antiplatelet strategies for specific high-risk scenarios.